SCHEMBL3034173

SCHEMBL3034173

CC#Cc1cc(C#N)cc(Oc2c(Cl)ccc(CNC(=O)c3[nH]cnc3Cl)c2F)c1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTGES O14684 2/20 0.36
EPHX2 P34913 2/20 0.34
HAO1 Q9UJM8 2/20 0.32
RORC P51449 2/20 0.32
P2RX7 Q99572 1/20 0.32
LMNA P02545 1/20 0.31
KLKB1 P03952 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.30
CASP6 P55212 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3035905 0.94 CYP3A4 (0.45) CYP3A4CYP2C9CYP2C19EPHX2HAO1
SCHEMBL3029972 0.92 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19EPHX2HAO1
SCHEMBL3027499 0.91 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL13982260 0.91 PTGES (0.38) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL13560513 0.91 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3028060 0.90 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19EPHX2RORC
SCHEMBL3016733 0.90 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3800467 0.90 CYP3A4 (0.51) CYP3A4CYP2C9CYP2C19EPHX2HAO1
SCHEMBL3023587 0.90 CYP3A4 (0.49) CYP3A4CYP2C9CYP2C19PTGESEPHX2
SCHEMBL3032726 0.90 RORC (0.42) CYP3A4CYP2C9CYP2C19PTGESEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US claimed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US claimed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP claimed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO claimed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885CYP2C9 720/4885CYP2C19 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.